432 related articles for article (PubMed ID: 16006134)
41. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
42. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
43. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.
Vivacqua G; Biagioni F; Yu S; Casini A; Bucci D; D'Este L; Fornai F
J Chem Neuroanat; 2012 Jul; 44(2):76-85. PubMed ID: 22580273
[TBL] [Abstract][Full Text] [Related]
44. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
[TBL] [Abstract][Full Text] [Related]
45. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
46. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.
Song DD; Shults CW; Sisk A; Rockenstein E; Masliah E
Exp Neurol; 2004 Apr; 186(2):158-72. PubMed ID: 15026254
[TBL] [Abstract][Full Text] [Related]
47. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
48. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
49. Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.
Bian MJ; Li LM; Yu M; Fei J; Huang F
Brain Res; 2009 Dec; 1302():256-64. PubMed ID: 19631617
[TBL] [Abstract][Full Text] [Related]
50. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
[TBL] [Abstract][Full Text] [Related]
51. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
52. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
53. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
54. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
[TBL] [Abstract][Full Text] [Related]
55. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease.
Gerlach M; Riederer P; Double KL
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S185-8. PubMed ID: 18585086
[TBL] [Abstract][Full Text] [Related]
56. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
[TBL] [Abstract][Full Text] [Related]
57. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
Yamakawa K; Izumi Y; Takeuchi H; Yamamoto N; Kume T; Akaike A; Takahashi R; Shimohama S; Sawada H
Biochem Biophys Res Commun; 2010 Jan; 391(1):129-34. PubMed ID: 19900407
[TBL] [Abstract][Full Text] [Related]
58. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
59. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
60. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Fornai F; Lazzeri G; Bandettini Di Poggio A; Soldani P; De Blasi A; Nicoletti F; Ruggieri S; Paparelli A
Ann N Y Acad Sci; 2006 Aug; 1074():84-9. PubMed ID: 17105905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]